For updated information about JADPRO Live 2021, please visit JADPROLive.com

CURRENT ISSUE Current Issue Cover
VOL 13 NO 1 • JAN/FEB 2022
IN THIS ISSUE

Resolving Not to Make New Year’s Resolutions

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, FAAN

Shared Decision-Making in Managing Breakthrough Cancer Pain in Patients With Advanced Cancer

Jeannine M. Brant,(1) PhD, APRN, AOCN®, FAAN, Debra Wujcik,(2) PhD, RN, FAAN, William N. Dudley,(3) PhD, Alison Petok,(4) MSW, LSW, Brooke Worster,(4) MD, Diane Jones,(1) MSN, NP, Kim Bosket,(1) RN, BSN, OCN®, Christian Brady,(1) MSN, AGNP, APRN, and Carrie Tompkins Stricker,(4) PhD, RN, ANP-BC

General and Unique Communication Skills Challenges for Advanced Practice Providers: A Mixed-Methods Study

Deborah Stein,(1) ACNP-BC, Kerry Cannity,(2) PhD, Richard Weiner,(1) NP, Shira Hichenberg,(1) Angelina Leon-Nastasi,(1) Smita Banerjee,(1) PhD, and Patricia Parker,(1) PhD

 
Section Seperator

TODAY'S NEWS

Study Suggests Lack of Benefit With the ...

In an analysis reported in the Journal of Clinical...

Clinical Score May Assist in Guiding Pep...

Peptide receptor radionuclide therapy (PRRT) with ...

Selecting Patients With Barrett’s Esopha...

In a study reported in The Lancet Oncology, Piloni...

Anthracycline Plus Taxane Reduces Risk o...

In a large patient-level meta-analysis of 16 trial...

EPOV Anne Blaes

Invited discussant Anne Blaes, MD, Associate Profe...

More News From Today More News
Section Seperator

EDITORIALS & COMMENTARY

Advanced Practitioners as Allies and Advocates

Advanced practitioners (APs) are a growing proportion of the health-care team...

Rare Myeloproliferative Neoplasm w/CSF3R

Cases of chronic neutrophilic leukemia (CNL) are extremely rare and easily missed...

Management of Carcinoid Syndrome

Diarrhea is often a presenting symptom in patients with neuroendocrine tumors...

APs: Collaborators in Radiation Oncology

Advanced practitioners, including physician assistants and nurse practitioners, are medical professionals with...

Axicabtagene Ciloleucel: CAR T-Cell Therapy

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T-cell therapy that has demonstrated efficacy...

More Editorials & Commentary More Tweets
 
Section Seperator

PREVIOUS HIGHLIGHTS

Gemcitabine/Eribulin in Cisplatin-Inelig...

In the final analysis from a phase II California C...

Deintensified Chemoradiotherapy for HPV-...

In a phase II trial reported in the Journal of Cli...

USPSTF Recommendation on Risk Assessment...

As reported in JAMA, the U.S. Preventive Services ...

Incidence of HPV-Associated Head and Nec...

In a study by Mahal et al published in Cancer Epid...

Racial Reporting and Representation in O...

New research published by Loree et al in JAMA Onco...

More Highlights More Highlights
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
 
 
Designed by Harborside
Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.